Panacea Biotec has received an approval for the allotment of 74,300 unrated, unlisted, redeemable, non-convertible debentures (NCDs), having the face value of Rs 1 lakh each, aggregating to Rs 743 crore on private placement basis. The Executive Committee of the Board of Directors of the Company at its meeting held on April 08, 2019, approved the same.
Panacea Biotec is a leading research based Biotechnology Company with established research, manufacturing and marketing capabilities. It is one of the largest vaccine producers and biotechnology companies in India.
